financetom
Business
financetom
/
Business
/
Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients
Dec 23, 2024 11:11 AM

01:45 PM EST, 12/23/2024 (MT Newswires) -- Eli Lilly ( LLY ) and Amgen ( AMGN ) filed a complaint Friday against the US Department of Health and Human Services, alleging that the agency unlawfully certified and recertified clinics that treat sexually transmitted diseases to participate in a federal drug discount program.

The plaintiffs said in the lawsuit that the court "should set aside the agency's unlawful certifications and recertifications of these ineligible entities and enjoin the agency from certifying or recertifying these entities in the future."

The Department of Health and Human Services did not immediately reply to a request for comment from MT Newswires.

Price: 791.19, Change: +23.43, Percent Change: +3.05

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UBS CEO against reducing bank's size in face of regulatory concerns
UBS CEO against reducing bank's size in face of regulatory concerns
Sep 5, 2025
BADEN, Switzerland, Sept 5 (Reuters) - UBS CEO Sergio Ermotti on Friday rejected reducing the bank's size amid pressure to do so from Swiss regulators following its emergency takeover of Credit Suisse. Ermotti told a business conference on Friday he was hopeful a sensible solution could be found on regulatory matters which are currently under discussion in Bern, but shrinking...
Broadcom shares rally on new AI deal, CEO's assurance
Broadcom shares rally on new AI deal, CEO's assurance
Sep 5, 2025
(Reuters) -Broadcom shares jumped 7% in premarket trading on Friday, as an upbeat outlook for artificial intelligence revenue and CEO Hock Tan's pledge to stay on for five more years reassured investors betting on the chipmaker's custom silicon strategy. The firm, one of the world's most valuable chipmakers, has become a key player in the generative AI boom by designing...
Work paused at Hyundai's US site after hundreds of workers detained in raid
Work paused at Hyundai's US site after hundreds of workers detained in raid
Sep 5, 2025
SEOUL (Reuters) -Up to 450 workers at a Hyundai Motor ( HYMLF ) facility under construction in Georgia have been detained in a major raid by U.S. authorities that has led to a pause in the project to build a car battery factory. The raid on Thursday has dealt a setback to the project, which is part of what would...
BioNTech, Duality score initial trial win with breast cancer precision drug
BioNTech, Duality score initial trial win with breast cancer precision drug
Sep 5, 2025
FRANKFURT Sept 5 (Reuters) - BioNTech and its partner Duality Biologics said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of slowing down disease progression. For COVID-19 vaccine maker BioNTech, the news marks the first success in a cancer trial that could potentially lead to market approval...
Copyright 2023-2026 - www.financetom.com All Rights Reserved